

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Marshall E. Kadin, MD	POSITION TITLE Professor		
eRA COMMONS USER NAME			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Northwestern U, Evanston IL	B.A.	1957-61	Liberal Arts
Northwestern U, Chicago IL	M.D.	1961-65	Medicine

Please refer to the application instructions in order to complete sections A, B, and C of the Biographical Sketch.

A. Positions

1965-1966 Internship, Milwaukee County General Hospital, Milwaukee, WI
 1966-1968 Residency, Pathology, Washington University Barnes Hospital, St. Louis, MO
 1968-1970 NIH Fellow, Surgical Pathology, Stanford University, Palo Alto, CA
 1970-1971 Chief of Pathology, U.S. Army Medical Corps, Republic of Vietnam
 1971-1972 Chief of Pathology, Sixth U.S. Army Medical Laboratory, Fort Baker, CA
 1972-1973 Fellow, Clinical Hematology, University of California, San Francisco, CA
 1973-1977 Assistant Professor of Medicine and Clinical Pathology, Univ. of California, San Francisco
 Research Associate, Cancer Research institute, Univ. of California, San Francisco
 Attending Physician in Medicine and Laboratory Medicine, Univ. of California, San Francisco
 1977-1982 Associate Professor of Laboratory Medicine and Pathology, Univ. of Washington, Seattle, WA
 1977-1984 Director of Hematology lab and Hematopathology, Univ. of Washington Hosp. Seattle, WA
 1980-1984 Associate Member, Fred Hutchinson Cancer Research Center, Seattle, WA
 1981-1982 Adjunct Associate Professor of Medicine, University of Washington, Seattle, WA
 1982-1984 Professor of Laboratory Medicine and Pathology, Adjunct Professor of Medicine, Univ. of Wash.
 Full Member, Fred Hutchinson Cancer Research Center
 1984 Visiting Professor, Dept. of Pathology, University of Kiel, Germany
 1984-2002 Associate Professor of Pathology, Harvard Medical School
 Director of Hematopathology, Beth Israel Hospital, Boston, MA
 1984-2005 Senior Pathologist, Beth Israel Hospital, Boston, MA
 1990-1996 Consultant in Pathology New England Deaconess Hospital
 1991-1995 Attending Physician, Autopsy Service, Beth Israel Hospital, Boston, MA
 1992-2002 Director, Hematopathology Fellowship Program, Beth Israel Hospital, Boston, MA
 1992-2005 Consultant in Dermatopathology, Harvard Medical School
 1998-2005 Associate Director, Cutaneous Oncology Program, Beth Israel Deaconess Medical Center
 1998-Present Member, Dana Farber Cancer Center
 2000-2001 Visiting Professor, Institute of Dermatology, University of Zurich
 2000-2002 Academic Associate, Quest Laboratories
 2002-2005 Consultant in Pathology, Beth Israel Deaconess Medical Center
 2002-present Associate Clinical Professor of Pathology, Harvard
 2002-present Image Bank Editor – American Society of Hematology
 2007-present Professor of Dermatology, Boston University, Boston, MA
 2007-present Staff Physician, Roger Williams Medical Center, Dept. of Dermatology & Skin Surgery,
 Providence, Rhode Island

Honors Phi Beta Kappa (1961), Tuition Scholarship, Northwestern University Medical School (1961-65)
 Bronze Star Medal for Meritorious Service in Vietnam (1971), University of Oregon Noble Wiley Jones Lecturer
 in Oncology (1984), Stowell-Orbison Award for sponsorship of outstanding resident paper-US/Canadian

Academy of Pathology (1997), Chosen one of "The Best Doctors in America" in Hematopathology (selected by physicians) published by Woodward and White 1992-93, 1994-95, 1996-98, 1998-2002, 2003-2006. Member, scientific subcommittees for immunohematology and lymphocyte biology, Am Soc of Hematology (1994-6) Past president Boston Chapter, Amer Assn for Cancer Res. Member, editorial board of Cancer, Blood, Amer Journ Surg Path, Human Pathology, Int J Hematology, American Journal of Dermatopathology

B. Selected peer-reviewed publications.

1. Wang HH, Myers T, Lach LJ, Hsieh CC, **Kadin ME**. Increased risk of lymphoid and non-lymphoid malignancies in patients with lymphomatoid papulosis. *Cancer* 1999, 86:1240-5.
2. Mori M, Mannuelli C, Pimpinelli N, Mavilia C, Maggi E, Santucci M, Bianchi B, Cappugi P, Giannotti B, **Kadin ME**. CD30-CD30L interaction in primary cutaneous CD30+ T-cell lymphomas: A clue to the pathophysiology of clinical regression. *Blood* 1999, 94: 3077-83.
3. Pfeifer W, Levi E, Petrogiannis-Halioitis T, Lehmann L, Wang Z, **Kadin ME**. A murine xenograft model for human CD30+ anaplastic large cell lymphoma: Successful growth inhibition with a CD30 activating antibody (HeFi-1). *Amer J Pathol* 1999, 155: 1353-59.
4. Schiemann WP, Pfeifer WM, Levi E, **Kadin ME**, Lodish HF. A deletion in the gene for transforming growth factor-beta type I receptor abolishes growth regulation by transforming growth factor-beta in a cutaneous T cell lymphoma. *Blood* 1999, 94: 2854-61.
5. Levi E, Wang Z, Petrogiannis-Halioitis T, Pfeifer WM, Kempf W, Drews R, **Kadin ME**. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: A possible mechanism for disease progression. *Journ Invest Dermatol* 2000, 115:1034-1040.
6. Li S, Ross DT, **Kadin ME**, Brown PO, Wasik MA. Comparative genome-scale analysis of gene expression profiles in T-cell lymphoma during malignant progression using a complementary DNA microarray. *Amer J Pathol* 2001, 158:1231-37.
7. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y, Saito I, Higashihara M, Mori S, **Kadin ME**, Watanabe T. Ligand-independent signaling by overexpressed CD30 drives NF-kB activation in Hodgkin- Reed Sternberg cells. *Oncogene* 2002, 21:2493-2503.
8. Dereure O, Levi E, Vonderheid EC, **Kadin ME**. Infrequent mutations of Fas but not p53 or Bax in early mycosis fungoides. A possible mechanism for accumulation of malignant T-lymphocytes in the skin. *Journ Invest Dermatol* 2002, 118: 949-956.
9. Horie R, Watanabe T, Ito K, Morisita Y, Watanabe M, Ishida T, Higashihara M, **Kadin ME**, Watanabe T. Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in Hodgkin/Reed-Sternberg cells. *American Journal of Pathology*, 160:1647-54, 2002. Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in Hodgkin/Reed-Sternberg cells. *Amer Journ Pathol* 2002, 160:1647-54.
10. Willenbrock K, Ichinohasama R, **Kadin ME**, Miura I, Terui T, Meguro K, Fukuhara O, DeCoteau JF, Hansmann ML. T-cell variant of classical Hodgkin's lymphoma with nodal and cutaneous manifestations demonstrated by single cell polymerase chain reaction. *Lab Invest* 2002, 82:1103-1109.
11. Kempf W, **Kadin ME**, Dvorak A, Lord CL, Burg NL, Koralnik IJ. Endogenous retroviral elements, but not exogenous retroviruses are present in CD30-positive lymphoproliferative disorders of the skin. *Carcinogenesis*, 2003, 24:301-6
12. Dereure O, Levi E, Vonderheid EC, **Kadin ME**. Improved sensitivity of T-cell clonality detection in mycosis fungoides by hand microdissection and heteroduplex analysis. *Arch Dermatol*, 2003, 139:1571-75.
13. Horie R, Watanabe T, Ito K, Morisita Y, Watanabe M, Ishida T, Higashihara M, **Kadin ME**. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells. *Amer Journ Pathol* 2003, 163:633-41,
14. Willers J, Dummer R, Kempf W, Kundig T, Burg G, **Kadin ME**. Proliferation of CD30+ T helper 2 cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand. *Clin Canc Res* 2003, 9:2744 9:2744-54.
15. Kleinhans M, Tun-Kyi A, Gilliet M, **Kadin ME**, Dummer R, Burg G, Nestle FO. Functional expression of the eotaxin receptor CCR3 in CD30 positive cutaneous lymphoma. *Blood*, 2003, 101:1487-93.
16. Burg G, Kempf W, Kazakov DV, Dummer R, Frosch PJ, Lange-Ionescu S, Nishikawa T, **Kadin ME**. Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich lymphoma, Clinicopathologic study of four cases and review of the literature. *Brit Journ Dermatol* 2003, 148:1-7.

17. Santucci M, Pimpinelli N, Massi D, **Kadin ME**, Meijer CHLM, Muller-Hermelink HK. Cytotoxic/Natural killer cell cutaneous lymphomas. *Cancer* 2003, 97:610-27.
18. Njisten T, Curiel C, **Kadin ME**. Lymphomatoid papulosis in children. *Arch Derm*, 2004, 240:306-312.
19. Ruebben A, Kempf W, **Kadin ME**, Zimmermann DR, Burg G. Multilineage progression of genetically unstable tumor subclones in cutaneous T-cell lymphoma revealed by microdissection and allelotyping. *Experimental Dermatology*, 2004, 13:472-83.
20. Adams AE, Zwicke J, Curiel C, **Kadin ME**, Falchuk KR, Drews R, Kupper TS. Aggressive cutaneous T cell lymphomas after TNF blockade. *Journ Am Acad Dermatol*, 2004, 4: 660-2.
21. Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K, Higashirahara M, **Kadin ME**, Watanabe T. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF- B activation in ALCL cells, *Cancer Cell* 2004, 5:353-364.
22. Franchina M, **Kadin ME**, Abraham LW. Regulation of the CD30 promoter in CD30+ cutaneous lymphomas. *Cancer Epidemiology, Biomarkers and Prevention*, 2005,14:1322-5.
23. Greisser J, Doebbeling U, Roos M, Mueller B, Schmid M, Burg G, **Kadin ME**, Kempf W. Apoptosis in CD30-positive lymphoproliferative disorders of the skin. *Experimental Dermatology* 2005, 14:380-85.
24. Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, **Kadin ME**, Abraham LJ, Watanabe T, Horie R. JunB induced by constitutive CD30-ERK1/2 MAPK signaling activates the CD30 promoter in 2005, 65: 7628-34.
25. **Kadin ME**. Pathobiology of CD30+ Cutaneous T-cell lymphomas. *Journal of Cutaneous Pathology*, 2006, Suppl 1, 10-17.
26. Lones MA, Heerema NA, Le Beau MM, Perkins SL, **Kadin ME**, Kjeldsberg CR, Sposto R, Meadows A, Siegel S, Buckley J, Abromowitch M, Cairo MS, Sanger WG. Complex secondary chromosome abnormalities in advanced stage anaplastic large cell lymphoma of children and adolescents: A report from CCG-E08, *Cancer Genetics and Cytogenetics*, 2006, 171:89-96. (Lead Article).
27. Lones MA, Heerema N, LeBeau M, Sposto R, Perkins S, **Kadin ME**, Kjeldsberg CR, Meadows A, Kersey J, Seigel S, Buckley H, Abromowitch M, Bergeron S, Sanger W. Chromosome abnormalities in advanced stage lymphoblastic lymphoma and childhood and adolescents: a report from CCG-E08, *Cancer Genetics and Cytogenetics*, 2007, 172: 1-11 (Lead Article).
28. Watanabe M, Dewan Z, Taira M, Shoda M, Honda M, Sata T, Higashirara M, **Kadin ME**, Watanabe T, Yamamoto N, Umezawa K, Horie R. I κ B independent induction of NF- κ B and its inhibition by DHMEQ in Hodgkin-Reed-Sternberg cells. *Laboratory Investigation*, 2007, 87:372-82.

Editorials, invited papers, book chapters in past 3 years

1. Younes A, **Kadin ME**. Tumor necrosis factor family of ligands and receptors: Clinical implications and emerging therapeutic applications in benign and malignant hematologic disorders. *Journal of Clinical Oncology*, 2003, 21:3526-34.
2. **Kadin ME**, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. *Seminars in Hematology*, 2003, 40:244-56, 1003.
3. **Kadin ME**. Extracutaneous origin of lymphomatoid papulosis. *Blood*, 2003, 102:3468.
4. **Kadin ME**, Carpenter C. Hidden Identity of Hodgkin/Reed-Sternberg cells, *Blood*, 2004, 103:7.
5. **Kadin ME**. Latest lymphoma classification is skin deep. *Blood*, 2005, 105:3759.
6. **Kadin ME**, Lui H, Kim Y, Hoppe R. CD30+ cutaneous lymphoproliferative disease (ALCL) and lymphomatoid papulosis. In *Non-Hodgkin's Lymphomas*, edited by Peter M. Mauch, James O. Armitage, Nancy Lee Harris, Bertrand Coiffier, Ricardo Dalla-Favera, Lippincott Williams and Wilkens, 2004, 321-343.
7. Kempf W, Willemze R, Jaffe ES, **Kadin ME**. CD30+ T-cell lymphoproliferative disorders of the skin. In *WH Classification of Tumours of the Skin*, IARC, pp.179-181, 2006.
8. Jaffe ES, Kerl H, **Kadin ME**. Hodgkin lymphoma. In *WHO Classification of Tumours of the Skin*, IARC, 207-208, 2006.
9. Loughran TP, Jr., **Kadin ME**. Large Granular Lymphocyte Leukemia. In *Williams Hematology*, 7th Edition, edited by Ernest Beutler, MD, Marshall Lichtman, MD, Barry S Collier, MD, and Thomas J Kipps, MD, Ph D, Mc Graw-Hill, 2004, 1395-7, 2006
10. **Kadin ME**. Ontogeny of lymphoid cells, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf, Marcel Dekker, pp.29-35, 2005.
11. **Kadin ME**. Ontogeny of lymphoid cells, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf,

Marcel Dekker, in press.

12. **Kadin ME.** The lymphoid system, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf, Marcel Dekker, pp 21-22, 2005
13. **Kadin ME.** Structure and function of secondary lymphoid tissues and skin, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf, Marcel Dekker, pps 23-36, 2005.
14. **Kadin ME.** Histo- and Cytomorphology, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf, Marcel Dekker, pp.37-38, 2005.
15. **Kadin ME.** Classification of nodal lymphomas in historical perspective, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf, Marcel Dekker, pp 79-82, 2005.
16. **Kadin ME.** Cutaneous manifestations of Hodgkin lymphoma, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf, Marcel Dekker, pp. 311-312, 2005.
17. Droc C, Cualing H, **Kadin ME.** Need for improved molecular/genetic classification of CD30+ lymphomas involving the skin. *Cancer Control*,14:1-9, 2007
18. **Kadin ME.** Cutaneous and other rare lymphomas in *Pediatric Hematologic Malignancies* edited by Howard Weinstein, Springer-Verlag, in press.
19. **Kadin ME.** Cutaneous CD30+ T-cell lymphoproliferative disorders. In *Diagnostic Hematopathology*, Editors Elaine S. Jaffe, Nancy L. Harris, James W. Vardiman, W.B. Saunders, in press.
20. **Kadin ME,** Campbell JJ, Uguccioni M. Lymphocyte homing and immunology of extranodal lymphoid tissues, in *Extranodal lymphoma*, edited by H. Stein and F. Cavalli, in press.

C. Research Support

Active

1P20 RR018757-01

The New Stem Cell Biology (COBRE)

5/30/07—9/29/08

Vincent Falanga, MD (PI)

Agency: NIH – NCRR

This multidisciplinary grant addresses the overall plasticity and specifics of bone marrow stem cells and possible conversion to other cell types, including skin, lung, muscle, and islet cells. The proposal studies the origin of the cells responsible for conversion, the mechanism of conversion and specifically the importance of fusion of the cells, the effect of prior chimerism, the role of radiation and mobilization and the effects of cytokine treatment both in vitro and in vivo. Attention is also focused on hot spots during the cell cycle that are important in stem cell differentiation.

Completed

Project Number -PO-CA93683

10/01/01-9/30/06

Thomas Kupper, MD, PI

Agency: NIH/NCI Spore in Skin Cancer

Title of Project (*or Subproject*)- Functional and Genomic Analysis of Cutaneous T-cell Lymphoma

The major goals of this project are to improve our ability to diagnose and treat cutaneous T-cell lymphoma (CTCL) and to generate new hypotheses about the biology of CTCL. My focus on the pathogenesis and spread of CD30+ CTCL which comprises approximately 20% of cutaneous lymphomas.

Agency: American Society of Hematology

7/01/04-12/31/04 (\$5,000)

Analysis of Fetal Microchimerism in Lymphomatoid Papulosis

Marshall Kadin, PI

The goal of this study was to test the hypothesis that skin lesions of female patients with lymphomatoid papulosis contain greater numbers of male cells than control skin specimens using the method of fluorescent in situ hybridization (FISH).